ClinicalTrials.gg
RecruitingNCT07650058Updated Jun 16, 2026

Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.

An interventional study of High-Glycemic Breakfast Containing Cereal and Fresh Mango and High-Glycemic Breakfast Containing Cereal and Table Sugar in Healthy Participants, sponsored by Ball State University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Ball State University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Feb 2026, registered Jun 2026).
  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,173 studies in Inflammation with a site in United States — 161 open to participants now, 214 under way, 6 of them phase 3. Inflammation · United States.

Planned enrollment
579th of 956
35 · median 45
Started
2026
with 42 others
No phase
462 of 1,173
66 open now
Primary completion
2026-07
later than 49 of 209 live
Registered
1,158th of 1,173
by date

Among the 1,173 studies in Inflammation with a site in United States, this one is the 579th largest by planned enrollment of the 956 interventional ones that give a count, is one of 43 that started in 2026, is one of 462 with no phase, reaches primary completion later than 49 of the 209 other live ones, and was the 1,158th registered.

Inflammation

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

Browse Inflammation studies →

Open to participants now

161 of the 1,173 studies in Inflammation with a site in United States are open now. Recruiting first, the newest first:

156 more — sign in →

All 161 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,173 studies in Inflammation with a site in United States, or all of them as a file.
02

Study summary

Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.

Read the detailed description

The investigators will use banked serum samples from an ongoing randomized crossover study to determine the effects of fresh mango as a substitute for added sugar on postprandial glucose and insulin in the context of high glycemic and low glycemic breakfasts. The investigators will use samples banked from the high glycemic meals and compare indicators of intestinal permeability and inflammation following corn flakes + fresh mango and corn flakes + sucrose. the samples come from recruited individuals with a BMI in the 18.5-35.0 kg/m2 range from the Ball State University campus and surrounding communities. Each participant (N=35) will complete two meal trials in random order. An indwelling intravenous catheter (IV) is placed in a forearm vein and a baseline blood sample is collected. Next, participants will consume one of the two test meals: (1) corn flakes with 2% milk + fresh mango and (2) corn flakes with 2% milk + sucrose. Corn flakes based meals reflect a commonly consumed breakfast food with high glycemic index. In each meal, total sugar (grams) will be identical, meals are nearly isocaloric (+/- ≤ 4 kcal) and macronutrients are matched.

After each meal, additional whole blood samples will be collected at 30-, 60-, 120-, and 180 minutes after participants take their first bite of food. Blood is collected into serum separator tubes, allowed to clot, centrifuged, and stored at -80 degrees C until study completion. Serum LPS, LBP, and sCD14 will be assayed in duplicate at all timepoints as indicators of intestinal permeability. Direct LPS measurement will be carried out using a cutting-edge assay (Pyrogene rFC; Lonza) that detects LPS in a single enzymatic step. LPS assays will be conducted with LPS-free consumables in sterile biosafety cabinet. LBP and sCD14 will be measured with commercially available ELISAs. Serum IL-6 will be assayed in duplicate at all time points as a measure of inflammation. IL-6 analyses will be measured externally at the Indiana University School of Medicine Translational Core on a high-sensitivity single-plex assay.

03

Conditions studied

  • Healthy Participants

Browse trials for

Keywords

  • fresh mango
  • inflammation
  • intestinal permeability
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 45 years.
  • between 18.5-35.0 kg/m2
  • Not pregnant or expecting to become pregnant (females only)
  • Not (females only).
  • No known chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)
  • No history of using tobacco/illicit drugs
  • No history of using glucose-lowering medications/supplements.
  • No history of using prescribed anti-inflammatory medications
  • Does not use over-the-counter anti-inflammatory medications ≥2x/week
  • Does not have a pacemaker.
  • No relevant food allergies/intolerances
  • Able to lay supine for at least ten minutes.

Exclusion criteria

Exclusion Criteria:

  • Not between the ages of 18-45
  • \< 18.5 kg/m2 or >35.0 kg/m2
  • Pregnant (females only)
  • status (females only).
  • Been diagnosed with a chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)
  • Uses tobacco products or any illicit drugs.
  • Uses glucose-lowering drugs/supplements.
  • Regularly takes anti-inflammatory drugs (more than 2x week).
  • Have a pacemaker.
  • Allergic to mango, wheat, gluten, and/or milk.
  • Unable to lay in supine position in the dark for at least ten minutes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Cereal Consumption with Fresh Mango

    During the Cereal and Fresh Mango arm, participants will consume a bowl of corn flakes with 2% milk sweetened with fresh mango.

    Other: High-Glycemic Breakfast Containing Cereal and Fresh Mango

  • Experimental
    Cereal Consumption with Table Sugar

    During the Cereal and Table Sugar arm, participants will consume a bowl of corn flakes with 2% milk sweetened with table sugar.

    Other: High-Glycemic Breakfast Containing Cereal and Table Sugar

Interventions

  • OtherHigh-Glycemic Breakfast Containing Cereal and Fresh Mango

    High-glycemic breakfast of 84 grams of corn flakes prepared with 355 mL of 2% milk and sweetened with 262 grams of fresh mango.

  • OtherHigh-Glycemic Breakfast Containing Cereal and Table Sugar

    High-glycemic breakfast of 84 grams of corn flakes prepared with 355 mL of 2% milk and sweetened with 36 grams of table sugar.

06

What researchers measure

Primary outcomes

  1. LPS

    The investigators will measure LPS at baseline and 30-, 60-, 120-, and 180- minutes after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1 year.

  2. LPS Binding Protein

    The investigators will measure LPS binding protein at baseline and 30-, 60-, 120-, and 180-minutes after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1 year.

  3. IL-6

    The investigators will measure IL-6 at baseline and 30-, 60-, 120-, and 180-minutes after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1 year.

Secondary outcomes

  1. sCD14

    The investigators will measure soluble CD14 at baseline and 30-, 60-, 120-, and 180-minutes after each meal. These measurements will take place immediately and a complete dataset will be compiled upon study completion.

    Time frame: Through study completion, up to 1 year.

  2. Acceptability

    The investigators will measure acceptability of each meal with a survey at each study visit once post-meal.

    Time frame: Through study completion, up to 1 year.

  3. Satiety

    The investigators will measure satiety through a survey at baseline and at 30-, 60-, 90-, 120-, 150-, and 180-minutes after the meal.

    Time frame: Through study completion, up to 1 year.

Other outcomes

  1. Body Composition

    The investigators will measure body composition using bioelectrical impedance (InBody).

    Time frame: Through study completion, up to 1 year.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jul 2026, 5 months after the start.

Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 5 months is below that.

Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 16, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jan 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07650058
Lead sponsor
Ball State University
Collaborators
National Mango Board
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Feb 1, 2026
Primary completion
Jul 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Bryant Keirns, PhD
Contact
bryant.keirns@bsu.edu
765-285-8356
Bryant Keirns, PhD
principal investigator · Ball State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion